Palak Shah1, Richard Ha2, Ramesh Singh3, William Cotts4, Eric Adler5, Michael Kiernan6, Michela Brambatti5, Karen Meehan4, Sheila Phillips3, Sumanth Kidambi2, Gregory P Macaluso4, Dipanjan Banerjee2, Dierdre Mooney6, Duc Pham7, Victor D Pretorius5. 1. Department of Heart Failure and Transplantation, Inova Heart and Vascular Institute, Falls Church, Virginia. Electronic address: palak.shah@inova.org. 2. Department of Cardiac Surgery, Stanford University, Palo Alto, California. 3. Department of Heart Failure and Transplantation, Inova Heart and Vascular Institute, Falls Church, Virginia. 4. Department of Heart Failure and Transplantation, Advocate Christ Medical Center, Chicago, Illinois. 5. Department of Heart Failure and Transplantation, University of California San Diego, San Diego, California. 6. Department of Heart Failure and Transplantation, Tufts University, Boston, Massachusetts. 7. Department of Cardiac Surgery, Northwestern University, Chicago, Illinois.
Abstract
BACKGROUND: Severe right ventricular failure necessitating a right ventricular assist device (RVAD) complicates 6% to 11% of left ventricular assist device (LVAD) implants. Patient outcomes for those receiving durable continuous-flow VADs in a biventricular configuration (i.e., BiVAD) have been reported in limited case series. METHODS: Data from United States centers with ≥ 6 BiVAD implants were collected. Characteristics and outcomes of patients receiving contemporaneous (i.e., same surgery) vs staged implantation of the HVAD as a BiVAD were compared. RESULTS: From 2011 to 2017, 46 patients received durable BiVADs and had the following characteristics: median age, 46 years (interquartile range [IQR], 19-67 years), non-ischemic cardiomyopathy (80%), bridge to transplant (83%), Interagency Registry for Mechanically Assisted Circulatory Support Profile 1 or 2 (92%), use of temporary circulatory support (37%), right atrial pressure 19 mm Hg (IQR, 14-23 mm Hg), and cardiac index of 1.6 liters/min/m2 (IQR, 1.2-2.1 liters/min/m2). Operative mortality was 33%. Equal numbers of patients received a right atrial or right ventricular implant. Contemporaneous BiVAD implantation occurred in 31 patients (67%), and compared with 15 patients (33%) with staged implants, these patients had a shorter intensive care unit length of stay of 12 days (IQR, 7-23 days) vs 42 days (IQR, 28-48 days, p = 0.035) and were more likely to be discharged from the hospital on BiVAD support (61% vs 27%, p = 0.04). RVAD thrombosis developed in 17 patients (37%). Patients with contemporaneous BiVAD implants had a 1-year survival of 74% compared with 40% in staged BiVAD patients (p = 0.11). CONCLUSIONS: Patients receiving durable BiVADs represent a critically ill patient population with severe biventricular failure who have high operative mortality and RVAD thrombosis rates. The 1-year survival for patients receiving contemporaneous BiVADs in experienced centers mirrors other contemporary durable biventricular support strategies.
BACKGROUND: Severe right ventricular failure necessitating a right ventricular assist device (RVAD) complicates 6% to 11% of left ventricular assist device (LVAD) implants. Patient outcomes for those receiving durable continuous-flow VADs in a biventricular configuration (i.e., BiVAD) have been reported in limited case series. METHODS: Data from United States centers with ≥ 6 BiVAD implants were collected. Characteristics and outcomes of patients receiving contemporaneous (i.e., same surgery) vs staged implantation of the HVAD as a BiVAD were compared. RESULTS: From 2011 to 2017, 46 patients received durable BiVADs and had the following characteristics: median age, 46 years (interquartile range [IQR], 19-67 years), non-ischemic cardiomyopathy (80%), bridge to transplant (83%), Interagency Registry for Mechanically Assisted Circulatory Support Profile 1 or 2 (92%), use of temporary circulatory support (37%), right atrial pressure 19 mm Hg (IQR, 14-23 mm Hg), and cardiac index of 1.6 liters/min/m2 (IQR, 1.2-2.1 liters/min/m2). Operative mortality was 33%. Equal numbers of patients received a right atrial or right ventricular implant. Contemporaneous BiVAD implantation occurred in 31 patients (67%), and compared with 15 patients (33%) with staged implants, these patients had a shorter intensive care unit length of stay of 12 days (IQR, 7-23 days) vs 42 days (IQR, 28-48 days, p = 0.035) and were more likely to be discharged from the hospital on BiVAD support (61% vs 27%, p = 0.04). RVAD thrombosis developed in 17 patients (37%). Patients with contemporaneous BiVAD implants had a 1-year survival of 74% compared with 40% in staged BiVADpatients (p = 0.11). CONCLUSIONS:Patients receiving durable BiVADs represent a critically illpatient population with severe biventricular failure who have high operative mortality and RVAD thrombosis rates. The 1-year survival for patients receiving contemporaneous BiVADs in experienced centers mirrors other contemporary durable biventricular support strategies.
Authors: Jaime-Jürgen Eulert-Grehn; Pia Lanmüller; Christoph Starck; Felix Hennig; Stephan Jacobs; Volkmar Falk; Evgenij Potapov Journal: Ann Cardiothorac Surg Date: 2021-05
Authors: Mark S Goodin; Michael S Showalter; David J Horvath; Barry D Kuban; Christine R Flick; Anthony R Polakowski; Kiyotaka Fukamachi; Jamshid H Karimov Journal: ASAIO J Date: 2021-11-10 Impact factor: 3.826
Authors: Silvia Mariani; Tong Li; Karl Bounader; Dietmar Boethig; Alexandra Schöde; Jasmin S Hanke; Jana Michaelis; L Christian Napp; Dominik Berliner; Guenes Dogan; Roberto Lorusso; Axel Haverich; Jan D Schmitto Journal: Ann Cardiothorac Surg Date: 2021-03
Authors: Tomasz K Urbanowicz; Hanna Baszyńska-Wachowiak; Anna Olasińska-Wiśniewska; Marcin Misterski; Sebastian Stefaniak; Marcin Ligowski; Marek Jemielity Journal: Kardiochir Torakochirurgia Pol Date: 2020-07-20
Authors: Takuma Miyamoto; Yuichiro Kado; David J Horvath; Barry D Kuban; Shiva Sale; Kiyotaka Fukamachi; Jamshid H Karimov Journal: JTCVS Open Date: 2020-06-20
Authors: Yaron D Barac; Ronen Toledano; Oliver K Jawitz; Jacob N Schroder; Mani A Daneshmand; Chetan B Patel; Dan Aravot; Carmelo A Milano Journal: JTCVS Open Date: 2022-01-22
Authors: Andrew Y Lin; Hao Tran; Michela Brambatti; Eric Adler; Victor Pretorius; Travis Pollema; Jonathan C Hsu; Gregory K Feld; Kurt Hoffmayer; Frederick Han; David Krummen; Gordon Ho Journal: J Interv Card Electrophysiol Date: 2019-12-14 Impact factor: 1.900
Authors: James Farag; Kei Woldendorp; Nicholas McNamara; Paul G Bannon; Silvana F Marasco; Antonio Loforte; Evgenij V Potapov Journal: Ann Cardiothorac Surg Date: 2021-05